Carter speaks ''We are pleased to be partnering with SUDA as...

Carter speaks

''We are pleased to be partnering with SUDA as they develop ZolpiMist commercial opportunities around the world,” Aytu CEO Josh Disbrow said in a statement.
SUDA, a drug delivery company focused on oro-mucosal administration, has already signed sublicensing agreements in key markets with large, multinational drug companies and has agreements in place in China, Chile, Brazil and throughout Southeast Asia.
Under their deal, SUDA will pay Aytu a portion of each upfront and milestone payment received from sublicensees, and Aytu will receive ongoing royalty payments on sales generated by SUDA's sublicensees as ZolpiMist is launched in various territories.
SUDA CEO Stephen Carter said the company “has a number of discussions in place to further the global footprint of the ZolpiMist brand.”